Skip to main content

Advertisement

Table 1 Observational studies examining active vitamin D administration in patients with CKD or on dialysis

From: Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies

Author Year Country # Participants Study period Patient category Treatment Comparator Vitamin D dosage Study design Statistical methods Follow-up duration months ITT analysis NOS scale
Teng et al. 2003 United States 67399 1999 to 2001 Prevalent HD patients Paricalcitol Calcitriol NA Historical cohort multicenter study Baseline Cox model; as-treated analysis 36 no 6
Shoji et al. 2004 Japan 242 1992 to 1998 Prevalent HD patients Alfacalcidol No treatment NA Prospective cohort single center study Baseline Cox model 76 no 9
Teng et al. 2005 United States 51037 1996 to 1999 Prevalent HD patients Calcitriol or paricalcitol No treatment NA Historical cohort multicenter study Time-dependent Cox model; marginal structural model 24 yes 6
Melamed et al. 2006 United States 1007 1995 to 1998 Incident HD and PD patients Calcitriol No treatment NA Prospective cohort multicenter study Baseline and time-dependent Cox models 48 no 5
Kalantar-Zadeh et al. 2006 United States 58058 2001 to 2003 Prevalent HD patients Paricalcitol No treatment NA Historical cohort multicenter study Baseline and time-dependent Cox models 24 no 7
Tentori et al. 2006 United States 14967 1999 to 2004 Prevalent HD patients Calcitriol; paricalcitol; doxercalciferol No treatment; each other NA Historical cohort multicenter study Baseline and time-dependent Cox models; as treated analysis 60 yes 7
Kovesdy et al. 2008 United States 520 1990 to 2007 CKD stage 2 to 4 patients Calcitriol No treatment 1.75-3.5ug/week Prospective cohort single center study Baseline Cox model 48 no 6
Naves-Diaz et al. 2008 Argentina; Brazil; Colombia; Chile; Mexico; Venezuela 16004 2000 to 2004 Prevalent HD patients Calcitriol or alfacalcidol No treatment NA Historical cohort multicenter study Time-dependent Cox model 54 yes 6
Shinaberger et al. 2008 United States 34307 2001 to 2004 Prevalent HD patients Paricalcitol No treatment 1.7-30.8ug/week Historical cohort multicenter study Baseline Cox model 30 no 7
Shoben et al. 2008 United States 1418 1999 to 2007 CKD stage 3 to 4 patients Calcitriol No treatment   Historical cohort multicenter study Baseline Cox model; as-treated analysis 48 yes 8
Wolf et al. 2008 United States 9303 2004 to 2005 Incident HD patients Calcitriol; paricalcitol; doxercalciferol No treatment; stratified by race NA Prospective cohort multicenter study Baseline Cox model 12 no 5
Tentori et al. 2009 France; Germany; Italy; Japan; Spain; United Kingdom; United States; Australia; Belgium; Canada; New Zealand; Sweden 38066 1996 to 2009 Incident HD patients Calcitriol; paricalcitol; doxercalciferol No treatment; each other NA Prospective cohort multicenter study Baseline and time-dependent Cox models; Marginal structural model 30 no 5
Peter et al. 2009 United States 193830 1999 to 2004 Prevalent and incident HD Calcitriol; paricalcitol; doxercalciferol No treatment 0.25-3.5ug/week* Historical cohort multicenter study Time-dependent Cox model 63 no 6
Chang et al. 2009 Taiwan 702 1993 to 2004 Incident HD Calcitriol No treatment 0.75-6.0ug/week Retrospective cohort single center study Baseline Cox model 140 no 6
Konta et al. 2010 Japan 466 2003 to 2008 Incident HD Calcitriol; falecalcitriol; maxacalcitol No treatment 1.1-5.1ug/week; 1.4-2.6ug/week; 2.6-5.4ug/week Prospective cohort multicenter study Baseline Cox model 60 no 7
Sugiura et al. 2010 Japan 665 1992 to 2008 Incident HD Alfacalcidol No treatment 1.75-3.5ug/week Retrospective cohort single center study Baseline Cox model 132 no 6
Jean et al. 2011 France 648 2005 to 2009 Prevalent HD patients Alfacalcidol No treatment 1.75-9ug/week Prospective cohort multicenter study Baseline Cox model 42 no 5
Brancaccio et al. 2011 Italy 2378 2006 to 2007 Incident HD patients Calcitriol; paricalcitol No treatment 1.9-3.3ug/week; 11.2-15.9ug/week Prospective cohort multicenter study Time-dependent Cox model 18 no 5
Dierkes et al. 2011 Germany 650 NA NA Calcitrol; cholecalciferol No treatment NA Prospective cohort multicenter study NA 24 NA NA
Ogawa et al. 2012 Japan 190 2005 to 2010 Prevalent HD patients Alfacalcidol No treatment 3.4-7.0ug/week Prospective cohort single center study Baseline Cox model 60 no 9
  1. Asterisk (*) indicate the calcitriol equivalent doses. Paricalcitol and doxercalciferol doses were converted to calcitriol equivalent doses with ratios 4.6:1 for paricalcitol:calcitriol and 3.1:1 for doxercalciferol:calcitriol.